Relationship Between EGFR Mutation And Clinicopathological Features And Prognosis In NSCLC Patients

Objectives This study is aimed to investigate the relations between epidermal growth factor receptor(EGFR)gene mutation and clinicopathological characteristics and prognosis of non-small cell lung cancer(NSCLC).Methods We retrospectively analyzed the clinicopathological characteristics and prognosis of 446 patients with EGFR detection who were diagnosed with NSCLC in Tangshan People's Hospital from January 2015 to October 2018.Results 1 EGFR mutations were identified in 51.6%.The mutation status of EGFR was related to sex,smoking history,pathological type,TNM stage,T stage and specimen type(?2=42.866,?2=20.440,?2=23.989,?2=12.986,?2=16.869,?2=8.308;P<0.001,P<0.001,P<0.001,P=0.005,P=0.001,P=0.004).Sex and pathological type were independent influencing factors of EGFR mutation in patients with NSCLC.EGFR mutation status was related to gender,smoking history,specimen type and T stage in adenocarcinoma patients(?2=32.276,?2=14.978,?2=4.998,?2=13.566;P<0.001,P<0.001,P=0.025,P=0.004);gender was an independent influencing factor for EGFR mutation in adenocarcinoma patients;in addition,there was a correlation between pathological subtypes and EGFR mutations(P=0.001);there was no significant correlation between pathological subtypes and EGFR mutant subtypes(P=0.072).EGFR mutations were related to gender in nonadenocarcinoma patients.2 It was found that there was no significant correlation between different EGFR mutation subtypes and clinicopathological characteristics by analyzing the differences between 207 cases of different EGFR mutation subtypes and clinicopathological characteristics(P>0.05).3 There was no significant correlation between the mutation state of EGFR and the occurrence of distant metastatic events(P>0.05).There was no significant correlation between EGFR mutation and the number of distant metastatic organs(P>0.05).There was no significant difference between different subtypes of EGFR mutation and distant metastasis.4 The median progression free survival(m PFS)analysis of 446 patients found that m PFS and pathological type(?2=13.025,P<0.001),EGFR mutation status(?2=32.739,P<0.001),targeted therapy(?2=4.175,P=0.041),whether surgery(?2=116.508,P<0.001),T stage(?2=64.124,P<0.001),N stage(?2=68.291,P<0.001)and TNM stage(?2=147.094,P<0.001)was related;The m PFS of EGFR wild-type patients was 12 months,which was much lower than the 35 months of mutant patients;The m PFS of patients with non-adenocarcinoma,EGFR wild type,T4,N3,IV,unoperated and receiving targeted therapy was significantly shortened.EGFR mutation status,TNM stage,and whether surgery was an independent prognostic factor that affects m PFS(P=0.001,P<0.001,P=0.001).Median overall survival(m OS)and gender(?2= 9.792,P=0.002),EGFR mutation status(?2=25.919,P<0.001),whether surgery(?2=125.694,P<0.001),T Staging(?2=53.747,P<0.001),N staging(?2=69.499,P<0.001)and TNM staging(?2=208.160,P<0.001)are related,and the difference was statistically significant;The m OS of EGFR wild-type patients is 30 months,far lower than the 47 months of EGFR mutant patients;The m OS analysis showed that the m OS of male,EGFR wild-type,T4,N3,IV and non-operative patients was significantly shortened.TNM stage,EGFR mutation status,and whether surgery is an independent influencing factor of m OS.Conclusions 1 The mutation rate of EGFR is higher in female,nonsmoking,acinar adenocarcinoma,stage I,T1 and surgical patients with NSCLC.2 EGFR wild type,unoperated,and stage IV are independent risk factors that affect the prognosis of NSCLC patients.Figure13;Table18;Reference 177...